Effect of perioperative use of parecoxib on chronic post-surgical pain in elderly patients after hepatectomy: a prospective randomized controlled study
Abstract Background Chronic post-surgical pain (CPSP) has a negative impact on the recovery, quality of life, and physical functioning of elderly patients. This study aimed to test the superiority of parecoxib vs. placebo in preventing chronic post-hepatectomy pain in elderly patients under combined...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
BMC,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_df2f8ea55ed848bebfd23ef3a51cdd2e | ||
042 | |a dc | ||
100 | 1 | 0 | |a Xiaodong Ge |e author |
700 | 1 | 0 | |a Yan Pan |e author |
700 | 1 | 0 | |a Danfeng Jin |e author |
700 | 1 | 0 | |a Ying Wang |e author |
700 | 1 | 0 | |a Shengjin Ge |e author |
245 | 0 | 0 | |a Effect of perioperative use of parecoxib on chronic post-surgical pain in elderly patients after hepatectomy: a prospective randomized controlled study |
260 | |b BMC, |c 2021-06-01T00:00:00Z. | ||
500 | |a 10.1186/s40360-021-00501-1 | ||
500 | |a 2050-6511 | ||
520 | |a Abstract Background Chronic post-surgical pain (CPSP) has a negative impact on the recovery, quality of life, and physical functioning of elderly patients. This study aimed to test the superiority of parecoxib vs. placebo in preventing chronic post-hepatectomy pain in elderly patients under combined general-epidural anesthesia. Methods A total of 105 elderly patients undergoing hepatectomy under combined general-epidural anesthesia were randomized into the parecoxib or placebo group. The primary outcome was the proportion of patients with CPSP 3 months postoperatively. The secondary outcomes included the Short-Form McGill Pain Questionnaire score in CPSP-positive responders, acute pain intensity, postoperative analgesic demand, inflammatory markers change, and postoperative complications within 28 days. Results The parecoxib group provided a non-significant absolute 9.1% reduction in the rate of CPSP compared to the placebo group (P = 0.34). The average chronic pain visual analog scale in the parecoxib group was lower than that in the placebo group (P = 0.04). Significantly less moderate-to-severe acute pain at rest (P = 0.04) and with coughing (P < 0.001), less patient-controlled epidural analgesia (PCEA) consumption (P = 0.01), and less rescue analgesia (P < 0.001) were observed in the parecoxib group compared to the placebo group. Furthermore, no between-group difference was observed in inflammatory markers (P > 0.05) and postoperative complications (P = 0.65). Conclusions Parecoxib reduced the prevalence of CPSP in elderly patients after hepatectomy under combined general-epidural anesthesia from 44.4 to 35.3% with no statistical significance. Moreover, significantly alleviated CPSP intensity and improved acute pain management were observed. Trial registration This study was retrospectively registered in the Chinese Clinical Trial Registry (URL: http://www.chictr.org.cn/edit.aspx?pid=56961&htm=4 ) on August 3, 2020 ( ChiCTR-2,000,035,198 ). | ||
546 | |a EN | ||
690 | |a Parecoxib | ||
690 | |a Chronic post-surgical pain | ||
690 | |a Elderly | ||
690 | |a Hepatectomy | ||
690 | |a Multimodal analgesia | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Toxicology. Poisons | ||
690 | |a RA1190-1270 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-12 (2021) | |
787 | 0 | |n https://doi.org/10.1186/s40360-021-00501-1 | |
787 | 0 | |n https://doaj.org/toc/2050-6511 | |
856 | 4 | 1 | |u https://doaj.org/article/df2f8ea55ed848bebfd23ef3a51cdd2e |z Connect to this object online. |